Conversely, high post-treated soluble EGFR extracellular domain levels correlated with tumor size reduction on post-treatment metabolic SUV response assessment (bias adjusted Spearman's rho = −0.49, z-test p = 0.03; β = −0.42 se = 0.23, F test p = 0.08). The gene discussed is EGFR; the disease is neoplasm.